Press coverage about Insulet (NASDAQ:PODD) has trended somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insulet earned a daily sentiment score of 0.04 on Accern’s scale. Accern also gave news stories about the medical instruments supplier an impact score of 45.8439319690028 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment Analysis’s scoring:

Several brokerages have recently weighed in on PODD. Morgan Stanley upped their price objective on shares of Insulet from $55.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday, November 3rd. Barclays initiated coverage on shares of Insulet in a report on Friday, September 15th. They set an “overweight” rating and a $65.00 price objective on the stock. BidaskClub upgraded shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Friday, August 25th. Leerink Swann restated an “outperform” rating and issued a $74.00 target price (up previously from $65.00) on shares of Insulet in a report on Thursday, October 12th. Finally, Zacks Investment Research upgraded shares of Insulet from a “sell” rating to a “hold” rating and set a $68.00 target price on the stock in a report on Thursday, October 12th. Eight analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $61.07.

Insulet (PODD) traded up $0.72 on Monday, hitting $70.48. 451,592 shares of the company were exchanged, compared to its average volume of 502,809. The company has a current ratio of 4.88, a quick ratio of 4.42 and a debt-to-equity ratio of 4.65. Insulet has a 12 month low of $36.68 and a 12 month high of $72.99.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The company had revenue of $121.80 million for the quarter, compared to analyst estimates of $114.02 million. During the same quarter in the prior year, the business posted ($0.05) EPS. The firm’s revenue was up 28.4% compared to the same quarter last year. equities analysts forecast that Insulet will post -0.42 EPS for the current fiscal year.

In other news, Director James C. Mullen acquired 2,500 shares of Insulet stock in a transaction on Monday, November 13th. The stock was acquired at an average cost of $67.45 per share, with a total value of $168,625.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 2.60% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Insulet (PODD) Stock Price” was posted by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was stolen and reposted in violation of US and international copyright and trademark laws. The original version of this news story can be viewed at

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Insider Buying and Selling by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Co. and related companies with's FREE daily email newsletter.